BAJAJ BROKING

Notification
No new Notification messages
Inventurus Knowledge Solutions IPO is Open!
Apply for the Inventurus Knowledge Solutions IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
NSE BSE
kwality pharmaceuticals limite stock

Kwality Pharmaceuticals Limite Share Price

838.6 -32.05 (-3.68%)
Dec 13 2024 03:30 PM Pharmaceuticals NSE: KPL

Kwality Pharmaceuticals Limite Share Price Update

As of the latest trading session, Kwality Pharmaceuticals Limite share price is currently at 838.6, which is down by -32.05 from its previous closing. Today, the stock has fluctuated between 835.00 and 850.00. Over the past year, Kwality Pharmaceuticals Limite has achieved a return of 124.76 %. In the last month alone, the return has been -5.31 %. Read More...

Kwality Pharmaceuticals Limite Performance

Day Range

Low835.00 High850.00
838.60

52 Week Range

Low 356.10 High 961.15
838.60

Kwality Pharmaceuticals Limite Share Price

539997

KPL

img img img img
No Data Available

Open Price

850.00

Prev. Close

870.65

Volume (Shares)

16608.00

Total traded value

140.19

Upper Circuit

914.15

Lower Circuit

827.15

Note: The current prices & values are delayed, Login to your account for live updates.

Kwality Pharmaceuticals Limite Fundamentals


(Standalone)

Market Cap (Cr) 870.14
PE Ratio (TTM) 29.95
Book Value / Share 233.21
Beta 0.67
ROE 13.74%
EPS (TTM) 33.16
Dividend Yield 0.00%
Net Profit Qtr (Cr) 8.49

Kwality Pharmaceuticals Limite Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition

Revenue

Net income

Particulars SEP 2024 (Values in Cr)
Revenue 90.03
Operating Expense 77.67
Net Profit 8.49
Net Profit Margin (%) 9.43
Earnings Per Share (EPS) 8.18
EBITDA 19.90
Effective Tax Rate (%) 32.59
Particulars JUN 2024 (Values in Cr)
Revenue 80.08
Operating Expense 69.22
Net Profit 8.37
Net Profit Margin (%) 10.45
Earnings Per Share (EPS) 8.06
EBITDA 17.64
Effective Tax Rate (%) 24.86
Particulars MAR 2024 (Values in Cr)
Revenue 91.98
Operating Expense 79.22
Net Profit 4.50
Net Profit Margin (%) 4.89
Earnings Per Share (EPS) 4.33
EBITDA 14.34
Effective Tax Rate (%) 28.04
Particulars DEC 2023 (Values in Cr)
Revenue 78.10
Operating Expense 68.93
Net Profit 7.70
Net Profit Margin (%) 9.85
Earnings Per Share (EPS) 7.42
EBITDA 17.32
Effective Tax Rate (%) 21.16
Particulars SEP 2023 (Values in Cr)
Revenue 69.65
Operating Expense 61.67
Net Profit 6.26
Net Profit Margin (%) 8.98
Earnings Per Share (EPS) 6.03
EBITDA 15.50
Effective Tax Rate (%) 23.75
Particulars MAR 2024 (Values in Cr)
Revenue 307.17
Operating Expense 270.44
Net Profit 23.98
Net Profit Margin (%) 7.80
Earnings Per Share (EPS) 23.11
EBITDA 61.37
Effective Tax Rate (%) 23.76
Particulars MAR 2023 (Values in Cr)
Revenue 250.99
Operating Expense 211.64
Net Profit 19.47
Net Profit Margin (%) 7.75
Earnings Per Share (EPS) 18.45
EBITDA 46.70
Effective Tax Rate (%) 24.41
Particulars MAR 2022 (Values in Cr)
Revenue 456.13
Operating Expense 297.97
Net Profit 120.05
Net Profit Margin (%) 26.31
Earnings Per Share (EPS) 115.70
EBITDA 175.22
Effective Tax Rate (%) 25.74
Particulars MAR 2021 (Values in Cr)
Revenue 261.50
Operating Expense 241.29
Net Profit 15.42
Net Profit Margin (%) 5.89
Earnings Per Share (EPS) 14.86
EBITDA 30.85
Effective Tax Rate (%) 29.26
Particulars MAR 2020 (Values in Cr)
Revenue 138.68
Operating Expense 131.47
Net Profit 8.43
Net Profit Margin (%) 6.07
Earnings Per Share (EPS) 8.13
EBITDA 18.03
Effective Tax Rate (%) 24.32
Particulars MAR 2024 (Values in Cr)
Book Value / Share 215.31
ROE % 13.66
ROCE % 15.86
Total Debt to Total Equity 0.45
EBITDA Margin 22.19
Particulars MAR 2023 (Values in Cr)
Book Value / Share 192.48
ROE % 16.57
ROCE % 18.50
Total Debt to Total Equity 0.38
EBITDA Margin 25.34
Particulars MAR 2022 (Values in Cr)
Book Value / Share 173.81
ROE % 99.66
ROCE % 94.93
Total Debt to Total Equity 0.40
EBITDA Margin 38.40
Particulars MAR 2021 (Values in Cr)
Book Value / Share 58.16
ROE % 28.21
ROCE % 23.78
Total Debt to Total Equity 0.72
EBITDA Margin 11.62
Particulars MAR 2020 (Values in Cr)
Book Value / Share 43.57
ROE % 20.10
ROCE % 17.26
Total Debt to Total Equity 0.78
EBITDA Margin 12.83
Particulars MAR 2024 (Values in Cr)
Book Value / Share 216.98
ROE % 13.74
ROCE % 15.90
Total Debt to Total Equity 0.44
EBITDA Margin 22.29
Particulars MAR 2023 (Values in Cr)
Book Value / Share 193.93
ROE % 16.56
ROCE % 18.47
Total Debt to Total Equity 0.38
EBITDA Margin 25.41
Particulars MAR 2022 (Values in Cr)
Book Value / Share 175.17
ROE % 98.62
ROCE % 94.24
Total Debt to Total Equity 0.39
EBITDA Margin 38.42
Particulars MAR 2021 (Values in Cr)
Book Value / Share 59.47
ROE % 28.55
ROCE % 23.96
Total Debt to Total Equity 0.71
EBITDA Margin 11.80
Particulars MAR 2020 (Values in Cr)
Book Value / Share 44.62
ROE % 20.03
ROCE % 17.33
Total Debt to Total Equity 0.75
EBITDA Margin 13.02
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 5.94
Total Assets 394.20
Total Liabilities 394.20
Total Equity 222.58
Share Outstanding 10376198
Price to Book Ratio 1.89
Return on Assets (%) 6.03
Return on Capital (%) 7.42
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 7.36
Total Assets 353.63
Total Liabilities 353.63
Total Equity 199.06
Share Outstanding 10376198
Price to Book Ratio 1.59
Return on Assets (%) 5.47
Return on Capital (%) 6.7
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 12.95
Total Assets 340.59
Total Liabilities 340.59
Total Equity 179.78
Share Outstanding 10376198
Price to Book Ratio 3.31
Return on Assets (%) 35.23
Return on Capital (%) 51.32
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 5.80
Total Assets 166.26
Total Liabilities 166.26
Total Equity 59.85
Share Outstanding 10376198
Price to Book Ratio 0.94
Return on Assets (%) 9.10
Return on Capital (%) 16.02
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 1.53
Total Assets 132.69
Total Liabilities 132.69
Total Equity 44.96
Share Outstanding 10376198
Price to Book Ratio 0.57
Return on Assets (%) 6.26
Return on Capital (%) 10.89
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 5.03
Total Assets 397.57
Total Liabilities 397.57
Total Equity 225.94
Share Outstanding 10376198
Price to Book Ratio 1.89
Return on Assets (%) 6.03
Return on Capital (%) 7.4
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 6.09
Total Assets 356.58
Total Liabilities 356.58
Total Equity 202.02
Share Outstanding 10376198
Price to Book Ratio 1.59
Return on Assets (%) 5.45
Return on Capital (%) 6.66
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 10.87
Total Assets 342.67
Total Liabilities 342.67
Total Equity 182.55
Share Outstanding 10376198
Price to Book Ratio 3.31
Return on Assets (%) 35.03
Return on Capital (%) 50.75
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 5.13
Total Assets 168.78
Total Liabilities 168.78
Total Equity 62.50
Share Outstanding 10376198
Price to Book Ratio 0.94
Return on Assets (%) 9.13
Return on Capital (%) 15.85
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 1.14
Total Assets 134.68
Total Liabilities 134.68
Total Equity 47.09
Share Outstanding 10376198
Price to Book Ratio 0.57
Return on Assets (%) 6.26
Return on Capital (%) 10.74
Particulars MAR 2024 (Values in Cr)
Net Income 31.09
Cash from Operations 44.28
Cash from Investing -26.39
Cash from Financing -17.39
Net change in Cash -0.81
Free Cash Flow 74.12
Particulars MAR 2023 (Values in Cr)
Net Income 25.57
Cash from Operations 47.53
Cash from Investing -48.44
Cash from Financing 0.99
Net change in Cash -6.06
Free Cash Flow 95.21
Particulars MAR 2022 (Values in Cr)
Net Income 161.56
Cash from Operations 101.95
Cash from Investing -62.92
Cash from Financing 5.65
Net change in Cash 3.32
Free Cash Flow 157.10
Particulars MAR 2021 (Values in Cr)
Net Income 21.27
Cash from Operations 33.08
Cash from Investing -23.20
Cash from Financing 0.76
Net change in Cash 4.27
Free Cash Flow 56.48
Particulars MAR 2020 (Values in Cr)
Net Income 10.91
Cash from Operations 8.87
Cash from Investing -17.79
Cash from Financing 11.77
Net change in Cash 0.13
Free Cash Flow 29.65
Particulars MAR 2024 (Values in Cr)
Net Income 31.46
Cash from Operations 44.64
Cash from Investing -26.39
Cash from Financing -17.39
Net change in Cash -0.44
Free Cash Flow 74.48
Particulars MAR 2023 (Values in Cr)
Net Income 25.76
Cash from Operations 48.34
Cash from Investing -48.44
Cash from Financing 0.99
Net change in Cash -5.25
Free Cash Flow 96.01
Particulars MAR 2022 (Values in Cr)
Net Income 161.67
Cash from Operations 100.59
Cash from Investing -62.97
Cash from Financing 5.65
Net change in Cash 1.92
Free Cash Flow 155.75
Particulars MAR 2021 (Values in Cr)
Net Income 21.79
Cash from Operations 32.73
Cash from Investing -23.19
Cash from Financing 0.82
Net change in Cash 3.98
Free Cash Flow 56.13
Particulars MAR 2020 (Values in Cr)
Net Income 11.14
Cash from Operations 8.34
Cash from Investing -17.12
Cash from Financing 12.35
Net change in Cash 0.86
Free Cash Flow 29.08
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 64.13 36.86 3.50 491.45 37.54 / 77.70
BLISS GVS PHARMA LTD 175.85 22.01 1.83 1852.87 92.25 / 179.65
CIPLA LTD 1447.35 25.32 4.12 116889.80 1192.85 / 1702.00
FERMENTA BIOTECH LIMITED 403.70 140.17 4.09 1188.13 145.00 / 440.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 64.13 55.77 10.90 491.45 37.54 / 77.70
AMRUTAJAN HEALTH LTD 749.90 45.61 7.28 2168.01 556.05 / 861.40
ASTRAZENECA PHARMA IND LT 6603.60 128.25 24.30 16509.00 4050.15 / 8139.85
BLISS GVS PHARMA LTD 175.85 22.93 1.80 1852.87 92.25 / 179.65

Technicals

  • EMA & SMA
  • Resistance and Support
  • Price Change Analysis
- redarrow -
red-green-graph indicator
Bullish Moving Averages -
Bearish Moving Averages -
  • 5 Days 866.90
  • 26 Days 884.70
  • 10 Days 876.80
  • 50 Days 858.90
  • 12 Days 881.30
  • 100 Days 777.90
  • 20 Days 881.00
  • 200 Days 536.90
871.53
PIVOT
First Resistance 879.02
Second Resistance 887.38
Third Resistance 894.87
First Support 863.17
Second Support 855.68
Third Support 847.32
RSI 41.92
MACD -3.33
Commodity Channel Index (CCI) -217.88
ADX 21.37
Williams % R -80.33

Over 1 Month

down

-5.31

Over 3 Months

down

-0.32

Over 6 Months

down

58.31

Over 1 Year

down

124.76

Over 3 Years

down

-3.04

Over 5 Years

down

108.46

Kwality Pharmaceuticals Limite Future

Future: Price

25 May
0 100 200 300 400 500 600

Discount/Premium

25 May
0 1 2 3 4 5 6 7

Active Calls

25 May
0 500 1000 1500 2000 2500 3000

Active Puts

25 Jul
0 500 1000 1500 2000 2500

Kwality Pharmaceuticals Limite Shareholding Pattern

  • Shareholding Summary
  • Historical Promotor Holding
  • Historical MF Holding
  • Historical FII Holding

Holding

Public
45.15
Promoter Holdings
54.82
FII
0.0
DII
0.02
Promoter Shares(Pledge Percentage)
0.0
Name Category Shares Shares%
Ramesh Arora Shareholding of Promoter and Promoter Group 2698684.0 26.01
Ajay Arora Shareholding of Promoter and Promoter Group 1410638.0 13.59
Aditya Arora Shareholding of Promoter and Promoter Group 1240091.0 11.95
Deepak Bansal Public Shareholding 1103174.0 10.63
Manohar Devabhaktuni Public Shareholding 516735.0 4.98
Dheeraj Kumar Lohia Public Shareholding 198958.0 1.92
Kadayam Ramnathan Bharat Public Shareholding 195000.0 1.88
Jani Bhasha Shaik Public Shareholding 150000.0 1.45
Anju Arora Shareholding of Promoter and Promoter Group 135634.0 1.31
Geeta Arora Shareholding of Promoter and Promoter Group 111500.0 1.07
Onkar Singh Public Shareholding 109700.0 1.06
Jugal Kishore Huf Shareholding of Promoter and Promoter Group 92350.0 0.89
Aarti Bajaj Shareholding of Promoter and Promoter Group 75.0 0.0

Kwality Pharmaceuticals Limite

  • Dividend
  • Bonus
  • Split
Ex-Date Dividend Amt. Dividend Type Record Date Instrument Type
2017-01-05 0.6 Interim 2017-01-06 Equity shares
Ex-Date Ex-Bonus Ratio
2017-10-12 2017-10-11 1:1
Ex-Date Old FV NEW FV Record Date

Learn More About Stocks

About Kwality Pharmaceuticals Limite

Read More
  • Management structure
  • Board of directors
  • Committees of the board of directors

Companies Owned by Kwality Pharmaceuticals Limite

We have something for everyone

Explore More Investment Options

Stocks

Secure and enhance your financial future today

investment-card-icon

IPOs

Your gateway to future financial opportunities

investment-card-icon

MTF

Explore Buy Now Pay Later and boost your capital by up to 4x  

investment-card-icon

US Stocks

Discover opportunities to invest in elite FAANG stocks

investment-card-icon

Frequently Asked Questions

What is the Share Price of Kwality Pharmaceuticals Ltd?

Answer Field

The share price of Kwality Pharmaceuticals Ltd for NSE is ₹ 0.00 and for BSE is ₹ 838.60.

What is the Market Cap of Kwality Pharmaceuticals Ltd?

Answer Field

The market cap of Kwality Pharmaceuticals Ltd for NSE is ₹ 0.0 Cr. and for BSE is ₹ 8,70.10 Cr. as of now.

What is the 52 Week High and Low of Kwality Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of Kwality Pharmaceuticals Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 961.15 and ₹ 356.10.

How to Buy Kwality Pharmaceuticals Ltd share?

Answer Field

You can trade in Kwality Pharmaceuticals Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Kwality Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been 124.76%.

What is the Current Share Price of Kwality Pharmaceuticals Ltd?

Answer Field

Kwality Pharmaceuticals Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 838.60 as on Dec 13 2024 03:30 PM.

What is the Market Cap of Kwality Pharmaceuticals Ltd Share?

Answer Field

The market cap of Kwality Pharmaceuticals Ltd for NSE ₹ 0.0 & for BSE ₹ 8,70.10 as on Dec 13 2024 03:30 PM.

What is the P/E Ratio of Kwality Pharmaceuticals Ltd Share?

Answer Field

As on Dec 13 2024 03:30 PM the price-to-earnings (PE) ratio for Kwality Pharmaceuticals Ltd share is 29.95.

What is the PB ratio of Kwality Pharmaceuticals Ltd Share?

Answer Field

As on Dec 13 2024 03:30 PM, the price-to-book (PB) ratio for Kwality Pharmaceuticals Ltd share is 233.21.

How to Buy Kwality Pharmaceuticals Ltd Share?

Answer Field

You can trade in Kwality Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Kwality Pharmaceuticals Ltd Share on Bajaj Broking App?

Answer Field

To buy Kwality Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Kwality Pharmaceuticals Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs+ Users

icon-with-text

4.4+ App Rating

icon-with-text

4 Languages

icon-with-text

₹4700+ Cr MTF Book

icon-with-text
loader